(2) Semaglutide patent expires The patent for Semaglutide, used in Novo Nordisks blockbuster diabetic drugs Ozempic and Wegovy, expired on Friday last week (March 20, 2026), opening the doors for cheaper generics using the same formula to enter the market
Microdosing slows the pace deliberately your body sheds fat first and protects the lean tissue that drives your metabolism
This pharmacokinetic profile supports once-weekly subcutaneous administration, delivered via prefilled autoinjector pens available in 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg per 0.5 mL dose strengths [54]
Monitoring symptoms and working closely with a doctor are crucial for managing these risks while benefiting from the medication
Gut-liver axis: pathophysiological concepts and clinical implications
JAMA Netw Open (2018) 1(5):e182172